Cargando…

Study rationale and design of a study of EMPAgliflozin’s effects in patients with type 2 diabetes mellitus and Coronary ARtery disease: the EMPA-CARD randomized controlled trial

BACKGROUND: Recent trials have revealed that sodium-glucose co-transporter 2 inhibitors (SGLT2-i) are effective against hyperglycemia and also reduce micro- and macro-vascular complications in patients with type 2 diabetes mellitus (T2DM). Most of the beneficial cardiovascular effects have been inve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gohari, Sepehr, Reshadmanesh, Tara, Khodabandehloo, Hadi, Fathi, Mojtaba, Ahangar, Hassan, Arsang-Jang, Shahram, Ismail-Beigi, Faramarz, Ghanbari, Samin, Dadashi, Mohsen, Muhammadi, Muhammad Javad, Gohari, Sheida, Ghaffari, Saeid
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8242278/ https://www.ncbi.nlm.nih.gov/pubmed/34193056 http://dx.doi.org/10.1186/s12872-021-02131-1

Ejemplares similares

The effect of EMPAgliflozin on markers of inflammation in patients with concomitant type 2 diabetes mellitus and Coronary ARtery Disease: the EMPA-CARD randomized controlled trial
por: Gohari, Sepehr, et al.
Publicado: (2022)

The effect of sodium-glucose co-transporter-2 (SGLT2) inhibitors on blood interleukin-6 concentration: a systematic review and meta-analysis of randomized controlled trials
por: Gohari, Sepehr, et al.
Publicado: (2023)

The effect of dietary approaches to stop hypertension and ketogenic diets intervention on serum uric acid concentration: a systematic review and meta-analysis of randomized controlled trials
por: Gohari, Sepehr, et al.
Publicado: (2023)

Design and rationale of the EMPA‐VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure
por: Hundertmark, Moritz J., et al.
Publicado: (2021)

Placebo-Controlled, Double-Blind Study of Empagliflozin (EMPA) and Implantable Cardioverter-Defibrillator (EMPA-ICD) in Patients with Type 2 Diabetes (T2DM): Rationale and Design
por: Fujiki, Shinya, et al.
Publicado: (2020)

Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)
por: Zinman, Bernard, et al.
Publicado: (2014)

Low dose ultra-slow infusion thrombolytic therapy (LDUSITT) as an alternative option in a COVID-19 patient with free-floating right atrial thrombus: a case report and review of literature
por: Mahjani, Mahsa, et al.
Publicado: (2023)

Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA‐REG OUTCOME trial
por: Fitchett, David, et al.
Publicado: (2021)

Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME(®) trial
por: Fitchett, David, et al.
Publicado: (2020)

Impact of empagliflozin on subclinical left ventricular dysfunctions and on the mechanisms involved in myocardial disease progression in type 2 diabetes: rationale and design of the EMPA-HEART trial
por: Natali, Andrea, et al.
Publicado: (2017)

Following the results of the EMPA-REG OUTCOME trial with empagliflozin, is it possible to speak of a class effect?
por: Ampudia-Blasco, Francisco Javier, et al.
Publicado: (2017)

Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA‐REG OUTCOME
por: Pellicori, Pierpaolo, et al.
Publicado: (2020)

Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial
por: Inzucchi, Silvio E, et al.
Publicado: (2020)

Empagliflozin for Patients With Presumed Resistant Hypertension: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial
por: Ferreira, João Pedro, et al.
Publicado: (2020)

Cost‐effectiveness of empagliflozin in the UK in an EMPA‐REG OUTCOME subgroup with type 2 diabetes and heart failure
por: Reifsnider, Odette S., et al.
Publicado: (2020)

Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA‐REG OUTCOME trial
por: Verma, Subodh, et al.
Publicado: (2021)

Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA‐REG OUTCOME trial
por: Ferreira, João Pedro, et al.
Publicado: (2021)

Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial
por: Fitchett, David, et al.
Publicado: (2019)

Empa's New Clothes: The Untold Story of the Empa-Reg Outcome Trial
por: Alzaid, Aus
Publicado: (2017)

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(®) trial
por: Fitchett, David, et al.
Publicado: (2016)

Cost‐effectiveness analysis of empagliflozin treatment in people with Type 2 diabetes and established cardiovascular disease in the EMPA‐REG OUTCOME trial
por: Kansal, A., et al.
Publicado: (2019)

Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial
por: Hundertmark, Moritz J., et al.
Publicado: (2023)

Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA‐REG OUTCOME(®) trial
por: Kadowaki, Takashi, et al.
Publicado: (2019)

Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial
por: Ceriello, Antonio, et al.
Publicado: (2020)

Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA‐REG OUTCOME trial
por: Vaduganathan, Muthiah, et al.
Publicado: (2021)

Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial
por: Sattar, Naveed, et al.
Publicado: (2018)

Effect of empagliflozin on cardiorenal outcomes and mortality according to body mass index: A subgroup analysis of the EMPA‐REG OUTCOME trial with a focus on Asia
por: Ji, Qiuhe, et al.
Publicado: (2021)

Effect of empagliflozin on left ventricular contractility and peak oxygen uptake in subjects with type 2 diabetes without heart disease: results of the EMPA-HEART trial
por: Nesti, Lorenzo, et al.
Publicado: (2022)

NIMS and Empa announce STAM collaboration
por: Yoshida, Toyonobu, et al.
Publicado: (2014)

Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium–glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes
por: Yabe, Daisuke, et al.
Publicado: (2021)

Effect of empagliflozin on cardiac remodelling in South Asian and non-South Asian individuals: insights from the EMPA-HEART CardioLink-6 randomised clinical trial
por: Barbour, William, et al.
Publicado: (2023)

Bladder cancer in the EMPA-REG OUTCOME trial
por: Kohler, Sven, et al.
Publicado: (2017)

Does empagliflozin modulate the autonomic nervous system among individuals with type 2 diabetes and coronary artery disease? The EMPA-HEART CardioLink-6 Holter analysis
por: Garg, Vinay, et al.
Publicado: (2020)

The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non‐Asian populations of the EMPA‐REG OUTCOME trial of patients with type 2 diabetes and cardiovascular disease
por: Kaku, Kohei, et al.
Publicado: (2022)

Consumption of whole grains and risk of type 2 diabetes: A comprehensive systematic review and dose–response meta‐analysis of prospective cohort studies
por: Ghanbari‐Gohari, Faezeh, et al.
Publicado: (2022)

Fatal overdose from injection of human growth hormone; a case report and review of the literature
por: Erfanifar, Azam, et al.
Publicado: (2022)

Sodium glucose co-transporter 2 inhibition with empagliflozin on metabolic, cardiac and renal outcomes in recent cardiac transplant recipients (EMPA-HTx): protocol for a randomised controlled trial
por: Raven, Lisa Mary, et al.
Publicado: (2023)

Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial
por: Taheri, Hoda, et al.
Publicado: (2020)

EMPAS: Electron Microscopy Screening for Endogenous Protein Architectures
por: Kim, Gijeong, et al.
Publicado: (2020)

Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9o498ibkvdp7f85vo9vpvf880p